Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study
BackgroundAtopic dermatitis (AD) is a common inflammatory disease caused by a type 2 T helper cell–mediated immune response to environmental antigens. Approximately 1 in 5 patients with AD presents with moderate to severe disease, and treatments approved by the Food and Drug...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2023-08-01
|
| Series: | JMIR Dermatology |
| Online Access: | https://derma.jmir.org/2023/1/e41194 |
| _version_ | 1797328270672265216 |
|---|---|
| author | Torunn E Sivesind Ani Oganesyan Grace Bosma Camille Hochheimer Lisa M Schilling Robert Dellavalle |
| author_facet | Torunn E Sivesind Ani Oganesyan Grace Bosma Camille Hochheimer Lisa M Schilling Robert Dellavalle |
| author_sort | Torunn E Sivesind |
| collection | DOAJ |
| description |
BackgroundAtopic dermatitis (AD) is a common inflammatory disease caused by a type 2 T helper cell–mediated immune response to environmental antigens. Approximately 1 in 5 patients with AD presents with moderate to severe disease, and treatments approved by the Food and Drug Administration include emollients, topical glucocorticoids, and calcineurin inhibitors. Dupilumab, a fully human monoclonal antibody, improves AD via inhibition of interleukin-4 and interleukin-13.
ObjectiveOur aim was to characterize the prescribing patterns of dupilumab for AD in adults at a large university-affiliated health system.
MethodsA retrospective, observational cohort study was conducted using electronic data from the Observational Health Data Sciences and Informatics database, assessing data from the University of Colorado Medical Campus and its affiliates. The outcome measured was the prevalence of dupilumab prescribed for adults with AD (n=6421), between March 28, 2013, and March 28, 2021. We assessed whether the characteristics of patients who received dupilumab were different from those who did not. Each patient characteristic was assessed using a univariate logistic regression with the binary outcome of receiving or not receiving dupilumab.
ResultsWe found a population prevalence of 5.6% (6421/114,476) for AD. In our cohort, Black patients with AD were more than twice as likely to have received dupilumab compared to White patients (odds ratio 2.352, 95% CI 1.58-3.39). Patients with a diagnosis of atopic neurodermatitis were approximately twice as likely to have received dupilumab compared to those with other diagnostic variants of AD (odds ratio 1.87, 95% CI 1.01-3.22).
ConclusionsOur results demonstrate that both patient racial characteristics and specific AD diagnoses were associated with variations in dupilumab prescription patterns. |
| first_indexed | 2024-03-08T06:49:24Z |
| format | Article |
| id | doaj.art-b0e5c351b7f0430fae17cef928e40167 |
| institution | Directory Open Access Journal |
| issn | 2562-0959 |
| language | English |
| last_indexed | 2024-03-08T06:49:24Z |
| publishDate | 2023-08-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Dermatology |
| spelling | doaj.art-b0e5c351b7f0430fae17cef928e401672024-02-03T07:21:40ZengJMIR PublicationsJMIR Dermatology2562-09592023-08-016e4119410.2196/41194Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort StudyTorunn E Sivesindhttps://orcid.org/0000-0003-4805-0632Ani Oganesyanhttps://orcid.org/0000-0002-2305-6029Grace Bosmahttps://orcid.org/0000-0002-2397-2772Camille Hochheimerhttps://orcid.org/0000-0002-0984-0909Lisa M Schillinghttps://orcid.org/0000-0002-6878-189XRobert Dellavallehttps://orcid.org/0000-0001-8132-088X BackgroundAtopic dermatitis (AD) is a common inflammatory disease caused by a type 2 T helper cell–mediated immune response to environmental antigens. Approximately 1 in 5 patients with AD presents with moderate to severe disease, and treatments approved by the Food and Drug Administration include emollients, topical glucocorticoids, and calcineurin inhibitors. Dupilumab, a fully human monoclonal antibody, improves AD via inhibition of interleukin-4 and interleukin-13. ObjectiveOur aim was to characterize the prescribing patterns of dupilumab for AD in adults at a large university-affiliated health system. MethodsA retrospective, observational cohort study was conducted using electronic data from the Observational Health Data Sciences and Informatics database, assessing data from the University of Colorado Medical Campus and its affiliates. The outcome measured was the prevalence of dupilumab prescribed for adults with AD (n=6421), between March 28, 2013, and March 28, 2021. We assessed whether the characteristics of patients who received dupilumab were different from those who did not. Each patient characteristic was assessed using a univariate logistic regression with the binary outcome of receiving or not receiving dupilumab. ResultsWe found a population prevalence of 5.6% (6421/114,476) for AD. In our cohort, Black patients with AD were more than twice as likely to have received dupilumab compared to White patients (odds ratio 2.352, 95% CI 1.58-3.39). Patients with a diagnosis of atopic neurodermatitis were approximately twice as likely to have received dupilumab compared to those with other diagnostic variants of AD (odds ratio 1.87, 95% CI 1.01-3.22). ConclusionsOur results demonstrate that both patient racial characteristics and specific AD diagnoses were associated with variations in dupilumab prescription patterns.https://derma.jmir.org/2023/1/e41194 |
| spellingShingle | Torunn E Sivesind Ani Oganesyan Grace Bosma Camille Hochheimer Lisa M Schilling Robert Dellavalle Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study JMIR Dermatology |
| title | Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study |
| title_full | Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study |
| title_fullStr | Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study |
| title_full_unstemmed | Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study |
| title_short | Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study |
| title_sort | prescribing patterns of dupilumab for atopic dermatitis in adults retrospective observational cohort study |
| url | https://derma.jmir.org/2023/1/e41194 |
| work_keys_str_mv | AT torunnesivesind prescribingpatternsofdupilumabforatopicdermatitisinadultsretrospectiveobservationalcohortstudy AT anioganesyan prescribingpatternsofdupilumabforatopicdermatitisinadultsretrospectiveobservationalcohortstudy AT gracebosma prescribingpatternsofdupilumabforatopicdermatitisinadultsretrospectiveobservationalcohortstudy AT camillehochheimer prescribingpatternsofdupilumabforatopicdermatitisinadultsretrospectiveobservationalcohortstudy AT lisamschilling prescribingpatternsofdupilumabforatopicdermatitisinadultsretrospectiveobservationalcohortstudy AT robertdellavalle prescribingpatternsofdupilumabforatopicdermatitisinadultsretrospectiveobservationalcohortstudy |